Literature DB >> 36164269

An Unusual Presentation of Neurosarcoidosis.

Erdal Sarac1,2, Sergul A Erzurum1,3, Ali Arif1.   

Abstract

BACKGROUND Sarcoidosis is a systemic granulomatous disease of unknown cause, often affecting the lungs and lymphatic system. Neurologic manifestations of sarcoidosis, called "neurosarcoidosis", can present as cranial neuropathies and occur in an isolated fashion or alongside other systemic findings. These findings occur in about 5% to 15% of individuals, and mainly in women between the ages of 30 and 40 years. Within those subsets of patients who develop neurologic manifestations, ocular manifestations occur 13% to 79% of the time. Less common presentations include secondary glaucoma, intermediate or posterior inflammation, or other neuro-ophthalmic findings. CASE REPORT A 63-year-old White man initially presented with blurry vision, acute glaucoma, and other symptoms closely simulating hypertensive retinopathy. He later developed diplopia and was not accurately diagnosed by general ophthalmologists and a retina specialist. Due to the unusual presentation, hypertensive retinopathy was the incorrect initial working diagnosis and the patient continued to develop more severe symptoms. A multidisciplinary approach to patient care through a nephrology referral led to the final diagnosis of neurosarcoidosis. Prompt treatment improved renal function and ocular disturbances. CONCLUSIONS Retinal cotton-wool spots, glaucoma, and optic nerve swelling are rare presentations of neurosarcoidosis. Unusual vascular symptoms warrant consideration of all vascular diseases and prompts for collaboration through a multidisciplinary team. This case serves to highlight the importance of sarcoidosis as a differential, even in patients with no previous signs of granulomatous disease, and how a team-based approach between multiple specialties improves accuracy, timeliness, and treatment regimen.

Entities:  

Mesh:

Year:  2022        PMID: 36164269      PMCID: PMC9527853          DOI: 10.12659/AJCR.937125

Source DB:  PubMed          Journal:  Am J Case Rep        ISSN: 1941-5923


  15 in total

Review 1.  Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization.

Authors:  B A Rybicki; M Major; J Popovich; M J Maliarik; M C Iannuzzi
Journal:  Am J Epidemiol       Date:  1997-02-01       Impact factor: 4.897

Review 2.  Neuro-ophthalmic sarcoidosis.

Authors:  Robert P Baughman; Kenneth L Weiss; Karl C Golnik
Journal:  Eye Brain       Date:  2012-03-13

3.  Long-term follow-up of neurosarcoidosis.

Authors:  D Ferriby; J de Seze; T Stojkovic; E Hachulla; B Wallaert; A Destée; P Y Hatron; P Vermersch
Journal:  Neurology       Date:  2001-09-11       Impact factor: 9.910

Review 4.  Neuro-ophthalmic sarcoidosis.

Authors:  Yanny L Phillips; Eric R Eggenberger
Journal:  Curr Opin Ophthalmol       Date:  2010-11       Impact factor: 3.761

5.  Secondary glaucoma in patients with uveitis.

Authors:  J Merayo-Lloves; W J Power; A Rodriguez; M Pedroza-Seres; C S Foster
Journal:  Ophthalmologica       Date:  1999       Impact factor: 3.250

6.  Neurosarcoidosis: clinical presentations and course in 50 patients.

Authors:  V Oksanen
Journal:  Acta Neurol Scand       Date:  1986-03       Impact factor: 3.209

7.  Neurosarcoidosis As a Rare Differential Diagnosis for Single Or Multiple Lesions of the Nervous System.

Authors:  Christian Blume; Izabela Tuleta; Kay Nolte; Klaus W Eichhorn; Mark Jakob; Hans Clusmann; Thorsten Send
Journal:  Br J Neurosurg       Date:  2018-10-08       Impact factor: 1.596

8.  Ocular hypertension associated with ocular sarcoidosis.

Authors:  Salman Mirza; Tariq Saeed; Philip I Murray
Journal:  Ocul Immunol Inflamm       Date:  2007 Nov-Dec       Impact factor: 3.070

9.  Central nervous system sarcoidosis--diagnosis and management.

Authors:  J P Zajicek; N J Scolding; O Foster; M Rovaris; J Evanson; I F Moseley; J W Scadding; E J Thompson; V Chamoun; D H Miller; W I McDonald; D Mitchell
Journal:  QJM       Date:  1999-02

10.  Neurosarcoidosis.

Authors:  David Lacomis
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.